30 Jun BBS-Bioactive Bone Substitutes Plc: Trading on BBS’s warrants begins on First North Growth Market Finland

Posted at 10:21h in News by
0 Likes

BBS-Bioactive Bone Substitutes Plc   Company Announcement 28 June 2022 17.00 (CEST)

Trading on warrants 1-2022 (TO1) ja 2-2022 (TO2) issued by BBS-Bioactive Bone Substitutes Plc (“BBS” or the “Company”) begins on First North Growth Market Finland approximately on 1 July 2022.

Since only 8,084 warrants of series 1-2022 (TO1) and 2-2022 (TO2) each were subscribed in Sweden by a total of 199 subscribers, the warrants will not be subject to trading on First North Growth Market Sweden. BBS will provide the investors who have subscribed for warrants in Sweden and whose warrants have been delivered through the book-entry system maintained by Euroclear Sweden AB instructions on how to convert their warrants into warrants that are in the book-entry system maintained by Euroclear Finland Oy which can be traded on First North Growth Market Finland. The instructions will be delivered in September.

BBS-BIOACTIVE BONE SUBSTITUTES PLC

For more information:

Ilkka Kangasniemi, CEO,
tel. +35840 7080307, e-mail: ilkka.kangasniemi@bbs-artebone.fi

Liisa Hukka, CFO,
tel. +35840 0611038, e-mail: liisa.hukka@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, info@certifiedadviser.se

BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi. 

BBS-Bioactive Bone Substitutes Oyj:n shares have been listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

More information: www.bbs-artebone.fi

SOURCE:  BBS-Bioactive Bone Substitutes Oyj, Global Newswire, 28 June 2022

To find out more news from the industry head over to our news section – orthocg.com/news